Preclinical studies across various tumor types demonstrate that HIFU, when combined with immunotherapy, increases the expression of IFN-γ and granzyme B in the distant tumor microenvironment, enhances CD8+ T cell activation, augments tumor cell lysis, and extends survival [24,31-33]. This evidence concerns the gene IFNG and neoplasm.